Company Novo Nordisk A/S Sao Paulo

Equities

N1VO34

BRN1VOBDR005

Pharmaceuticals

Market Closed - Sao Paulo 15:47:20 2024-05-10 EDT 5-day change 1st Jan Change
82.89 BRL +2.71% Intraday chart for Novo Nordisk A/S +4.96% +32.69%

Business Summary

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:

- diabetes and obesity treatment products (92.6%);

- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.

Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Number of employees: 66,015

Sales per Business

DKK in Million2022Weight2023Weight Delta
Diabetes and Obesity Care
92.6 %
156,412 88.4 % 215,098 92.6 % +37.52%
Rare Disease
7.4 %
20,542 11.6 % 17,163 7.4 % -16.45%

Sales per region

DKK in Million2022Weight2023Weight Delta
United States
54.9 %
84,656 47.8 % 127,534 54.9 % +50.65%
EMEA
21.9 %
44,236 25.0 % 50,867 21.9 % +14.99%
Rest of the World
12.1 %
25,402 14.4 % 28,078 12.1 % +10.53%
China
7.2 %
16,209 9.2 % 16,687 7.2 % +2.95%
Canada
3.9 %
6,451 3.6 % 9,095 3.9 % +40.99%

Managers

Managers TitleAgeSince
Chief Executive Officer 58 90-12-31
Director of Finance/CFO 53 98-12-31
Chief Tech/Sci/R&D Officer - 15-09-30
Chief Tech/Sci/R&D Officer 57 17-12-31
Chief Operating Officer 54 91-12-31
Chief Tech/Sci/R&D Officer 54 98-12-31
Investor Relations Contact - 20-02-29
Human Resources Officer 47 06-12-31
General Counsel - -
Corporate Officer/Principal - 20-07-12

Members of the board

Members of the board TitleAgeSince
Director/Board Member 63 15-03-18
Chairman 61 17-03-22
Director/Board Member 68 18-02-28
Director/Board Member 54 19-03-20
Director/Board Member 59 17-03-22
Director/Board Member 62 18-02-28
Director/Board Member 57 21-03-24
Director/Board Member 58 91-12-31
Director/Board Member 49 18-03-21
Director/Board Member 52 18-03-21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 10 1,075,000,000 0 0 70.17 %
Stock B 1 3,390,128,000 3,133,044,823 ( 92.42 %) 51,700,000 ( 1.525 %)

Shareholders

NameEquities%Valuation
ATP Fondsmaeglerselskab A/S
8.698 %
298,789,780 8.698 % 38 200 M R$
Novo Holdings A/S (Investment Company)
5.536 %
190,183,000 5.536 % 24 315 M R$
48,963,707 1.425 % 6 260 M R$
Pensionskassernes Administration A/S
0.7345 %
25,229,760 0.7345 % 3 226 M R$
PFA Kapitalforvaltning Fondsmæglerselskab A/S
0.6898 %
23,696,970 0.6898 % 3 030 M R$
MP Investment Management A/S
0.5844 %
20,075,914 0.5844 % 2 567 M R$
Swedbank Robur Fonder AB
0.4784 %
16,434,239 0.4784 % 2 101 M R$
Capital International KK
0.2947 %
10,123,000 0.2947 % 1 294 M R$
Universal-Investment-Gesellschaft mbH (Invt Mgmt)
0.2305 %
7,919,037 0.2305 % 1 012 M R$
State Street Global Advisors Ltd.
0.2172 %
7,459,992 0.2172 % 954 M R$
NameEquities%Valuation
Novo Holdings A/S (Investment Company)
100.00 %
1,074,872,000 100.00 % 137 B R$
ANIMA Sgr SpA
0.0197 %
211,527 0.0197 % 27 M R$
Fineco Asset Management DAC
0.009413 %
101,181 0.009413 % 13 M R$
NS Partners SA
0.006408 %
68,876 0.006408 % 9 M R$
Kieger AG
0.002940 %
31,596 0.002940 % 4 M R$
Mercer Global Investments Europe Ltd.
0.002487 %
26,732 0.002487 % 3 M R$
OLZ AG
0.001913 %
20,557 0.001913 % 3 M R$
Union Bancaire Privée, UBP SA
0.001241 %
13,340 0.001241 % 2 M R$
Swissinvest Institut für Angewandte Finanzmarktanalysen GmbH
0.000698 %
7,500 0.000698 % 958 880 R$
DJE Kapital AG
0.000616 %
6,616 0.000616 % 845 860 R$
NameEquities%Valuation
Jennison Associates LLC
0.6138 %
21,084,614 0.6138 % 2 707 M R$
Merrill Lynch International
0.4066 %
13,968,876 0.4066 % 1 794 M R$
Renaissance Technologies LLC
0.4032 %
13,849,335 0.4032 % 1 778 M R$
Fisher Asset Management LLC
0.3995 %
13,724,718 0.3995 % 1 762 M R$
Fidelity Management & Research Co. LLC
0.3686 %
12,663,225 0.3686 % 1 626 M R$
Fayez Sarofim & Co.
0.3439 %
11,814,051 0.3439 % 1 517 M R$
Eaton Vance Management
0.3090 %
10,614,811 0.3090 % 1 363 M R$
Loomis, Sayles & Co. LP
0.2621 %
9,003,325 0.2621 % 1 156 M R$
Folketrygdfondet
0.2549 %
8,756,034 0.2549 % 1 124 M R$
Polen Capital Management LLC
0.2317 %
7,958,444 0.2317 % 1 022 M R$

Holdings

NameEquities%Valuation
48,963,707 1.43% 6,260,040,787 $
4,375,000 17.50% 68,672,756 $
9,817,546 12.14% 23,167,445 $

Company contact information

Novo Nordisk A/S

Novo Allé 1

2880, Bagsværd

+45 44 44 88 88

http://www.novonordisk.com
address Novo Nordisk A/S(N1VO34)

Group companies

NameCategory and Sector
Engineering & Construction
Financial Conglomerates
Pharmaceuticals: Major
Medical/Nursing Services
World Diabetes Foundation
Investment Trusts/Mutual Funds
Velfærdsfonden for Novo Nordisk A/S
Investment Trusts/Mutual Funds
Novo Nordisk Finance (Netherlands) BV
Finance/Rental/Leasing

Sales per Business

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
883.2 DKK
Average target price
908.7 DKK
Spread / Average Target
+2.88%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW